Atopic dermatitis: Emerging therapies

Eric Simpson, Jeremy Udkoff, Jenna Borok, Wynnis Tom, Lisa Beck, Lawrence F. Eichenfield

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis.

Original languageEnglish (US)
Pages (from-to)124-130
Number of pages7
JournalSeminars in Cutaneous Medicine and Surgery
Volume36
Issue number3
DOIs
StatePublished - Sep 1 2017

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Fingerprint Dive into the research topics of 'Atopic dermatitis: Emerging therapies'. Together they form a unique fingerprint.

  • Cite this

    Simpson, E., Udkoff, J., Borok, J., Tom, W., Beck, L., & Eichenfield, L. F. (2017). Atopic dermatitis: Emerging therapies. Seminars in Cutaneous Medicine and Surgery, 36(3), 124-130. https://doi.org/10.12788/j.sder.2017.0137